Investor Relations

Website Notice Block

Corporate Profile

MediWound is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, we are committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. 

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

November 21, 2023

NexoBrid ® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx ® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Operating cash runway through

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

November 21, 2023

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and